Cutting edge: Transplantation tolerance through enhanced CTLA-4 expression

被引:65
|
作者
Ariyan, C
Salvalaggio, P
Fecteau, S
Deng, SY
Rogozinski, L
Mandelbrot, D
Sharpe, A
Sayegh, MH
Basadonna, GP
Rothstein, DM
机构
[1] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA
[3] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA
[4] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01655 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Boston, MA 02115 USA
来源
JOURNAL OF IMMUNOLOGY | 2003年 / 171卷 / 11期
关键词
D O I
10.4049/jimmunol.171.11.5673
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Knockout and blocking studies have shown a critical role for CTLA-4 in peripheral tolerance, however, it is unknown whether augmenting CTLA-4 expression actually promotes tolerance. Here we demonstrate a specific and requisite role for CTLA-4 and its up-regulation in tolerance through anti-CD45RB. First, long-term murine islet allograft survival induced by anti-CD45RB is prevented by CTLA44g, which interferes with B7.-CTLA-4 interactions. Second, anti-CD45RB is ineffective in recipients lacking ng LA-4,B7-1, and B7-2. Incontrast, CTLA4-Ig, which targets B17 on allogeneic cells, promotes long-term engraftment in these mice. Moreover, anti-CD45Rb was effective in X-deficient controls expressing CTLA-4. Finally, in wildtype mice, CTLA-4 expression returned to baseline 17 days after receiving anti-CD45RB, and was refractory to further increase. Transplantation and anti-CD45RB therapy at this time could neither augment CTLA-4 nor prolong engraftment, These data demonstrate a specific role for CTLA-4 in anti-CD45RB-mediated tolerance and indicate that CTLA-4 up-regulation can directly promote allograft survival.
引用
收藏
页码:5673 / 5677
页数:5
相关论文
共 50 条
  • [1] Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo
    Salvalaggio, PRO
    Camirand, G
    Ariyan, CE
    Deng, S
    Rogozinski, L
    Basadonna, GP
    Rothstein, DM
    JOURNAL OF IMMUNOLOGY, 2006, 176 (04): : 2292 - 2298
  • [2] Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
    Corse, Emily
    Allison, James P.
    JOURNAL OF IMMUNOLOGY, 2012, 189 (03): : 1123 - 1127
  • [3] Cutting edge:: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous
    Bachmann, MF
    Köhler, G
    Ecabert, B
    Mak, TW
    Kopf, M
    JOURNAL OF IMMUNOLOGY, 1999, 163 (03): : 1128 - 1131
  • [4] Cutting edge: Tyrosine-independent transmission of inhibitory signals by CTLA-4
    Cinek, T
    Sadra, A
    Imboden, JB
    JOURNAL OF IMMUNOLOGY, 2000, 164 (01): : 5 - 8
  • [5] Cutting edge: A soluble form of CTLA-4 in patients with autoimmune thyroid disease
    Oaks, MK
    Hallett, KM
    JOURNAL OF IMMUNOLOGY, 2000, 164 (10): : 5015 - 5018
  • [6] CTLA-4 to overcome immunological tolerance to melanoma
    Hodi, F. Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 14 - 19
  • [7] CTLA-4 and tolerance - The biochemical point of view
    Chikuma, S
    Bluestone, JA
    IMMUNOLOGIC RESEARCH, 2003, 28 (03) : 241 - 253
  • [8] Augmentation of CTLA-4 expression by wortmannin: involvement of lysosomal sorting properties of CTLA-4
    Oki, S
    Kohsaka, T
    Azuma, M
    INTERNATIONAL IMMUNOLOGY, 1999, 11 (09) : 1563 - 1571
  • [9] Expression of CTLA-4 by human monocytes
    Wang, XB
    Giscombe, R
    Yan, Z
    Heiden, T
    Xu, D
    Lefvert, AK
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2002, 55 (01) : 53 - 60
  • [10] CTLA-4 trafficking and surface expression
    Valk, Elke
    Rudd, Christopher E.
    Schneider, Helga
    TRENDS IN IMMUNOLOGY, 2008, 29 (06) : 272 - 279